Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Abstract: The present invention relates to methods for treating or controlling schizophrenia in a mammal using compounds having the Formula (I), wherein M1 and M2 are defined in the application.

Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Abstract: An iso-thermalizing printer structure can be used to provide temperature uniformity across a width of a printer fuser roll or fuser belt. Various embodiments are contemplated, including a solid natural graphite shaft, a solid natural graphite core having a sleeve of metal such as aluminum, and other flexible and rigid structures which can comprise natural or synthetic graphite.

Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.

Abstract: An iso-thermalizing printer structure can be used to provide temperature uniformity across a width of a printer fuser roll or fuser belt. Various embodiments are contemplated, including a solid natural graphite shaft, a solid natural graphite core having a sleeve of metal such as aluminum, and other flexible and rigid structures which can comprise natural or synthetic graphite.

Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: This is a process to restore compression set properties of a silicone rubber fuser structure that has been damaged during the coating of the silicone with Teflon; Teflon is a registered trademark of DuPont. This restoration is achieved by re-baking the coated fuser roll at temperatures of 175° C. to 275° C. This will improve the compression set and will give the fuser structure improved life and provide better image quality.

Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.

Abstract: The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: This is a process to restore compression set properties of a silicone rubber fuser structure that has been damaged during the coating of the silicone with Teflon; Teflon is a registered trademark of DuPont. This restoration is achieved by re-baking the coated fuser roll at temperatures of 175° C. to 275° C. This will improve the compression set and will give the fuser structure improved life and provide better image quality.

Abstract: A layered structure, which may be used as a fuser member, comprises a first layer containing silicone; a second layer containing a fluoropolymer; and between the first and second layers, an adhesive layer comprising an aminosilane adhesive. In the layered structure, the second layer may additionally contain at least one of a polyamide-imide or a polyamide. Alternatively, or in addition, the adhesive layer may additionally contain fluoropolymer and at least one of a polyamide-imide or a polyamide.

Abstract: A fuser component useful in electrostatographic machines is provided. The fuser component has a substrate, and thereover a coating composition comprising a haloelastomer, such as, for example, a fluoroelastomer, and a filler having a particle size of less than about 3 micrometers and a particle hardness of greater than 3 on the Mohs' hardness scale.

Abstract: Disclosed is a fluoroelastomer loaded with an inorganic filler which is coupled to the fluoroelastomer by a titanate, zirconate or aluminate for use as a base layer and/or a release layer on a fuser, transfix, receiver or rheological transfer member in a copy machine. The coupled filler bonds tightly to the fluorocarbon matrix, significantly decreasing the wear rate of the member. These fillers also significantly increase the thermal conductivity of the compound as is often desirable in fusing applications.

Abstract: Nucleoside analogues have structure (2) wherein Q is H or a sugar moiety or sugar analogue or a modified sugar or a nucleic backbone or backbone analogue, W is an alkylene or alkenylene chain of 0-5 carbon atoms, any of which may carry a substituent R8, X is O or N or NR12 or CR10, X′ is O or S or N, provided that when X′ is O or S, then X is C, Y is CH or N, R6 is NH2 or SMe or SO2Me or NHNH2, each of R7 and R8 is independently H or F or alkyl or alkenyl or aryl or acyl or a reporter moiety, R12 is independently H or alkyl or alkenyl or aryl or acyl or a reporter moiety, and R10 is H or ═O or F or alkyl or aryl or a reporter moiety.